KRAS mutations represent the most common oncogene driver detected in about 30% of non-squamous NSCLC, usually occurring at codons 12–13 and associated with cigarette smoking.18,19 Several efforts have been made by the scientific community to understand the potential role of KRAS mutations as a therapeutic target in cancer cells, but no effective KRAS-inhibitors have been approved yet for clinical use. Here, KRAS is linked to cancer.